skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8847

Blood pressure-independent effect of candesartan on cardio-ankle vascular index in hypertensive patients with metabolic syndrome

Original Research

(1775) Views  (593) Full article downloads

Authors: Kanako Bokuda, Atsuhiro Ichihara, Mariyo Sakoda, et al

Published Date July 2010 Volume 2010:6 Pages 571 - 578
DOI: http://dx.doi.org/10.2147/VHRM.S11958

Kanako Bokuda1, Atsuhiro Ichihara1,2, Mariyo Sakoda1, Asako Mito1, Kenichiro Kinouchi1, Hiroshi Itoh1

1Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan; 2Department of Endocrinology and Anti-Aging Medicine, Keio University School of Medicine, Tokyo, Japan

Abstract: Angiotensin receptor blockers (ARBs) are known to reduce the cardiovascular risk in hypertensive patients. This study was designed to examine the effect of an ARB candesartan on subclinical atherosclerosis assessed by cardio-ankle vascular index (CAVI) in comparison with calcium channel blockers (CCBs) alone in hypertensive patients with metabolic syndrome (MetS). A total of 53 consecutive hypertensive patients with MetS were randomly assigned to the candesartan group, in which candesartan was added on, or the CCBs group, in which CCBs were added on. Clinical and biological parameters were obtained before and after the 12-month treatment period. The primary measure of efficacy was the %change in CAVI. When treated with candesartan, but not CCBs, CAVI significantly decreased from 8.7 to 7.7 by 11%. Blood pressure (BP) significantly decreased with both treatments, but the differences between groups were not significant. The changes in other parameters remained unchanged in both the groups. Analysis of covariance found that both the BP reduction and the therapy difference contributed to the decrease in CAVI, but the BP reduction was not involved in the decrease in CAVI caused by the difference in the therapy. Candesartan may be a better antihypertensive drug than CCBs to that subclinical atherosclerosis of patients with MetS.

Keywords: albuminuria, ambulatory blood pressure, calcium channel blockers, carotid ­intima-media thickness






Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Hematocrit and mean arterial blood pressure in pre- and postmenopause women
Berberine: metabolic and cardiovascular effects in preclinical and clinical trials
Comparison between automated and manual measurements of carotid intima-media thickness in clinical practice
MRI sagittal abdominal diameter is a stronger predictor of metabolic syndrome than visceral fat area or waist circumference in a high-risk vascular cohort
Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment
Diagnostic accuracy of dual-source CT angiography and coronary risk stratification
Assessing exchangeability in indirect and mixed treatment comparisons
Differential pharmacology and benefit/risk of azilsartan compared to other sartans
Accuracy of the ankle-brachial index using the SCVL®, an arm and ankle automated device with synchronized cuffs, in a population with increased cardiovascular risk
  • Join ISVH

    Be part of the World's leading experts in vascular health by joining the International Society of Vascular Health (ISVH)

  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University